Number of shares and votes in Calliditas Therapeutics

Rhea-AI Summary

On April 29, 2022, Calliditas Therapeutics AB announced the allotment of 830,586 common shares under its 2018 warrant program. This increase brings the total number of shares and votes to 53,172,170. The company focuses on developing treatments for orphan diseases, with products like TARPEYO approved by the FDA and ongoing trials for setanaxib targeting primary biliary cholangitis and head and neck cancer. Calliditas shares are listed on Nasdaq Stockholm under the ticker CALTX and on Nasdaq Global Select Market as CALT.

Positive

• Allotment of 830,586 common shares boosts total shares to 53,172,170.

Negative

• None.

STOCKHOLM, April 29, 2022 /PRNewswire/ -- During April, Calliditas Therapeutics AB (publ) has allotted 830,586 common shares within the company's warrant program issued in 2018. Thus, as of April 29, 2022, the number of shares and votes in the company amounts to 53,172,170.

For further information, please contact:

Mikael Widell, Investor relations

Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com

The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 10:00 a.m. CEST on April 29, 2022.

About Calliditas

Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product, TARPEYO^TM (budesonide) delayed release capsules, has been approved by the FDA and is the subject of a marketing authorization application (MAA) with the European Medicines Agency (EMA). Additionally, Calliditas is conducting a pivotal clinical trial with its NOX inhibitor product candidate setanaxib in primary biliary cholangitis and is initiating a head and neck cancer Phase 2 trial with setanaxib. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/number-of-shares-and-votes-in-calliditas-therapeutics,c3556446

The following files are available for download:

https://mb.cision.com/Main/16574/3556446/1571537.pdf

Number of shares and votes April 2022

View original content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-calliditas-therapeutics-301536113.html

SOURCE Calliditas Therapeutics

FAQ

What is the significance of the 830,586 common shares allotted by Calliditas on April 29, 2022?

The allotment of 830,586 common shares increases the total number of shares to 53,172,170, reflecting the company's capital structure adjustment.

What is Calliditas Therapeutics' focus in the biopharma sector?

Calliditas Therapeutics specializes in developing treatments for orphan diseases, particularly in renal and hepatic diseases.

What are Calliditas Therapeutics' stock symbols?

The company's common shares are listed on Nasdaq Stockholm as CALTX and its American Depositary Shares on Nasdaq Global Select Market as CALT.

When was the press release about the number of shares issued?

The press release was issued on April 29, 2022.